Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 13/20 | 0.44 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.35 |
| ▸ | HTR3A | P46098 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5737818 | 0.91 | HTR6 (0.44) | HTR6ACHEHTR2CKMT2A | |
| Trifluoroacetic Acid SCHEMBL5739463 | 0.78 | HTR6 (0.61) | HTR6TPSAB1DRD2 | |
| SCHEMBL3205539 | 0.71 | HTR6 (0.71) | HTR6DRD2MEN1KMT2A | |
| Trifluoroacetic Acid SCHEMBL5737813 | 0.70 | HTR6 (0.53) | HTR6DRD2MEN1KMT2A | |
| SCHEMBL3622706 | 0.69 | HTR6 (0.52) | HTR6 | |
| SCHEMBL3617274 | 0.69 | HTR6 (0.52) | HTR6 | |
| SCHEMBL3616913 | 0.69 | HTR6 (0.42) | HTR6 | |
| SCHEMBL3614533 | 0.67 | HTR6 (0.41) | HTR6 | |
| SCHEMBL28944310 | 0.67 | HTR6 (0.43) | HTR6DRD2MEN1KMT2A | |
| SCHEMBL3622100 | 0.66 | HTR6 (0.44) | HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060148818-A1 | Novel tetraydrospiro(piperdine-2,7'- pyrrolo{3,2-b}pyridine derivatives and novel in-dole derivatives useful in the treatment of 5-ht6 receptor-related disorders | BIOVITRUM AB (SE) | 2006-07-06 | — | — | US | claimed |
| EP-1675856-A1 | NOVEL TETRAYDROSPIRO{PIPERIDINE-2,7'-PYRROLO [3,2]PYRIDINE} DERIVATIVES AND NOVEL INDOLE DERIVATIVES USEFUL IN THE TREATMENT OF 5-HT6 RECEPTOR -RELATED DISORDERS | BIOVITRUM AB (SE) | 2006-07-05 | — | — | EP | claimed |
| WO-2005037834-A1 | NOVEL TETRAYDROSPIRO{PIPERIDINE-2,7’ -PYRROLO[3,2-b]PYRIDINE DERIVATIVES AND NOVEL INDOLE DERIVATIVES USEFUL IN THE TREATMENT OF 5-HT6 RECEPTOR -RELATED DISORDERS | BIOVITRUM AB (SE) | 2005-04-28 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148818-A1 | Novel tetraydrospiro(piperdine-2,7'- pyrrolo{3,2-b}pyridine derivatives and novel in-dole derivatives useful in the treatment of 5-ht6 receptor-related disorders | PTGDR, HTR6, HTR1B | HTR6 2/4885TPSAB1 523/4885HTR3A 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.